CLINICAL EEG and NEUROSCIENCE - Dynamic Memory Lab

More documents

Recommendations

Info

CLINICAL EEG and NEUROSCIENCE ©2007 VOL. 38 NO. 134. Blackwood D. P300, a state and a trait marker in schizophrenia.Lancet 2000; 355(9206): 771-772.35. Mathalon DH, Ford JM, Pfefferbaum A. Trait and stateaspects of P300 amplitude reduction in schizophrenia: a retrospectivelongitudinal study. Biol Psychiatry 2000; 47(5):434-449.36. Frodl-Bauch T, Gallinat J, Meisenzahl EM, Moller HJ, HegerlU. P300 subcomponents reflect different aspects of psychopathologyin schizophrenia. Biol Psychiatry 1999; 45(1):116-126.37. Santosh PJ, Malhotra S, Raghunathan M, Mehra YN. A studyof P300 in melancholic depression-correlation with psychoticfeatures. Biol Psychiatry 1994; 35(7): 474-479.38. Bruder GE, Towey JP, Stewart JW, Friedman D, Tenke C,Quitkin FM. Event-related potentials in depression: influenceof task, stimulus hemifield and clinical features on P3 latency.Biol Psychiatry 1991; 30(3): 233-246.39. Hansenne M, Pitchot W, Gonzalez Moreno A, Zaldua IU,Ansseau M. Suicidal behavior in depressive disorder: anevent-related potential study. Biol Psychiatry 1996; 40(2):116-122.40. Polich J, Ladish C, Bloom FE. P300 assessment of earlyAlzheimer’s disease. Electroencephalogr Clin Neurophysiol1990; 77(3): 179-189.41. Pfefferbaum A, Ford JM, Kraemer HC. Clinical utility of longlatency “cognitive” event-related potentials (P3): the cons.Electroencephalogr Clin Neurophysiol 1990; 76(1): 6-12; discussion1.42. Frodl T, Hampel H, Juckel G, Burger K, Padberg F, Engel RR,et al. Value of event-related P300 subcomponents in the clinicaldiagnosis of mild cognitive impairment and Alzheimer’sDisease. Psychophysiology 2002; 39(2): 175-181.43. Thomas A, Iacono D, Bonanni L, D’Andreamatteo G, OnofrjM. Donepezil, rivastigmine, and vitamin E in Alzheimer disease:a combined P300 event-related potentials/neuropsychologicevaluation over 6 months. Clin Neuropharmacol2001; 24(1): 31-42.44. Onofrj M, Thomas A, Luciano AL, Iacono D, Di Rollo A ,D’Andreamatteo G, et al. Donepezil versus vitamin E inA l z h e i m e r’s disease: II. mild versus moderate-severeA l z h e i m e r’s disease. Clin Neuropharmacol 2002; 25(4):2 0 7 - 2 1 5 .45. Pogarell O, Schulz C, Juckel G, Mueller-Siecheneder F, LauxG, Bahra R, et al. Auditory evoked P300 and treatmentresponse to donepezil in patients with Alzheimer´s disease.World J Biol Psychiatry 2001; 2: 264.46. Rockstroh B, Muller M, Wagner M, Cohen R, Elbert T. Eventrelatedand motor responses to probes in a forewarned reactiontime task in schizophrenic patients. Schizophr Res 1994;13(1): 23-34.47. Wagner M, Rendtorff N, Kathmann N, Engel RR. CNV, PINVand probe-evoked potentials in schizophrenics. ElectroencephalogrClin Neurophysiol 1996; 98(2): 130-143.48. Kornhuber HH, Deecke L. Changes in the brain potential involuntary movements and passive movements in man: readinesspotential and reafferent potentials. Pflugers A r c hGesamte Physiol Menschen Tiere 1965; 284: 1-17.49. Ashton CH, Marshall EF, Hassanyeh F, Marsh VR, Wright-Honari S. Biological correlates of deliberate self-harm behaviour:a study of electroencephalographic, biochemical andpsychological variables in parasuicide. Acta Psychiatr Scand1994; 90(5): 316-323.50. Javitt DC, Steinschneider M, Schroeder CE, Vaughan HG,Jr., Arezzo JC. Detection of stimulus deviance within primateprimary auditory cortex: intracortical mechanisms of mismatchnegativity (MMN) generation. Brain Res 1994; 667(2):192-200.51. Javitt DC, Schroeder CE, Steinschneider M, Arezzo JC,Ritter W, Vaughan HG, Jr. Cognitive event-related potentialsin human and non-human primates: implications for thePCP/NMDA model of schizophrenia. Electroencephalogr ClinNeurophysiol 1995; (suppl) 44: 161-175.52. Serra JM, Escera C, Sanchez-Turet M, Sanchez-Sastre J,Grau C. The H1-receptor antagonist chlorpheniraminedecreases the ending phase of the mismatch negativity of thehuman auditory event-related potentials. Neurosci Lett 1996;203(2): 77-80.53. Javitt DC, Doneshka P, Grochowski S, Ritter W. Impairedmismatch negativity generation reflects widespread dysfunctionof working memory in schizophrenia. Arch GenPsychiatry 1995; 52(7): 550-558.54. Catts SV, Shelley AM, Ward PB, Liebert B, McConaghy N,Andrews S, et al. Brain potential evidence for an auditorysensory memory deficit in schizophrenia. Am J Psychiatry1995; 152(2): 213-219.55. Shelley AM, Ward PB, Catts SV, Michie PT, Andrews S,McConaghy N. Mismatch negativity: an index of a preattentiveprocessing deficit in schizophrenia. Biol Psychiatry 1991;30(10): 1059-1062.56. Rosburg T, Kreitschmann-Andermahr I, Sauer H. Mismatchnegativity in schizophrenia research. An indicator of earlyprocessing disorders of acoustic information. [In German]Nervenarzt 2004; 75(7): 633-641.57. Baldeweg T, Klugman A, Gruzelier J, Hirsch SR. Mismatchnegativity potentials and cognitive impairment in schizophrenia.Schizophr Res 2004; 69(2-3): 203-217.58. Light GA, Braff DL. Mismatch negativity deficits are associatedwith poor functioning in schizophrenia patients. Arch GenPsychiatry 2005; 62(2): 127-136.59. Brockhaus-Dumke A, Tendolkar I, Pukrop R, Schultze-LutterF, Klosterkotter J, Ruhrmann S. Impaired mismatch negativitygeneration in prodromal subjects and patients with schizophrenia.Schizophr Res 2005; 73(2-3): 297-310.60. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K,et al. Schizophrenia, sensory gating, and nicotinic receptors.Schizophr Bull 1998; 24(2): 189-202.61. Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinicalcorrelates of P50 sensory gating abnormalities in patientswith schizophrenia. Schizophr Bull 2006; 32(4): 692-700.62. Adler LE, Waldo MC, Freedman R. Neurophysiologic studiesof sensory gating in schizophrenia: comparison of auditory andvisual responses. Biol Psychiatry 1985; 20(12): 1284-1296.63. Siegel C, Waldo M, Mizner G, Adler LE, Freedman R. Deficitsin sensory gating in schizophrenic patients and their relatives:evidence obtained with auditory evoked responses.Arch Gen Psychiatry 1984; 41(6): 607-612.64. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M,et al. Association of promoter variants in the alpha7 nicotinicacetylcholine receptor subunit gene with an inhibitory deficitfound in schizophrenia. Arch Gen Psychiatry 2002; 59(12):1085-1096.32
CLINICAL EEG and NEUROSCIENCE ©2007 VOL. 38 NO. 165. Leonard S, Breese C, Adams C, Benhammou K, Gault J,Stevens K, et al. Smoking and schizophrenia: abnormal nicotinicreceptor expression. Eur J Pharmacol 2000; 393(1-3):237-242.66. Leonard S, Gault J, Adams C, Breese CR, Rollins Y, AdlerLE, et al. Nicotinic receptors, smoking and schizophrenia.Restor Neurol Neurosci 1998; 12(2-3): 195-201.67. Leonard S, Adams C, Breese CR, Adler LE, Bickford P,Byerley W, et al. Nicotinic receptor function in schizophrenia.Schizophr Bull 1996; 22(3): 431-445.68. Freedman R, Adler LE, Bickford P, Byerley W, Coon H,Cullum CM, et al. Schizophrenia and nicotinic receptors.Harv Rev Psychiatry 1994; 2(4): 179-192.69. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA,Freedman R. Gating of auditory P50 in schizophrenics: uniquee ffects of clozapine. Biol Psychiatry 1996; 40(3): 181-188.70. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD.Neurophysiological evidence for a defect in inhibitory pathwaysin schizophrenia: comparison of medicated and drugfreepatients. Biol Psychiatry 1983; 18(5): 537-551.71. Nagamoto HT, Adler LE, McRae KA, Huettl P, Cawthra E,Gerhardt G, et al. Auditory P50 in schizophrenics on clozapine:improved gating parallels clinical improvement andchanges in plasma 3-methoxy-4-hydroxyphenylglycol.Neuropsychobiology 1999; 39(1): 10-17.72. Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG,Nagamoto HT, et al. Varied effects of atypical neuroleptics onP50 auditory gating in schizophrenia patients. Am JPsychiatry 2004; 161(10): 1822-1828.73. Myles-Worsley M, Ord L, Blailes F, Ngiralmau H, FreedmanR. P50 sensory gating in adolescents from a pacific islandisolate with elevated risk for schizophrenia. Biol Psychiatry2004; 55(7): 663-667.74. Waldo MC, Carey G, Myles-Worsley M, Cawthra E, Adler LE,Nagamoto HT, et al. Codistribution of a sensory gating deficitand schizophrenia in multi-affected families. Psychiatry Res1991; 39(3): 257-268.75. Clementz BA, Geyer MA, Braff DL. Poor P50 suppressionamong schizophrenia patients and their first-degree biologicalrelatives. Am J Psychiatry 1998; 155(12):1691-1694.76. Freedman R, Olincy A, Ross RG, Waldo MC, Stevens KE,Adler LE, et al. The genetics of sensory gating deficits inschizophrenia. Curr Psychiatry Rep 2003; 5(2):155-161.77. Buchsbaum M, Silverman J. Stimulus intensity control andthe cortical evoked response. Psychosom Med 1968; 30(1):12-22.78. Connolly JF, Gruzelier JH. Amplitude and latency changes inthe visual evoked potential to different stimulus intensities.Psychophysiology 1982; 19(6): 599-608.79. Dragutinovich S. Measurement and definition of changes inthe visual evoked potential to different stimulus intensities. IntJ Psychophysiol 1987; 5(2): 125-133.80. Carrillo-de-la-Pena MT. ERP augmenting/reducing and sensationseeking: a critical review. Int J Psychophysiol 1992;12(3): 211-220.81. Hegerl U, Gallinat J, Juckel G. Event-related potentials. Dothey reflect central serotonergic neurotransmission and dothey predict clinical response to serotonin agonists? J AffectDisord 2001; 62(1-2): 93-100.82. Juckel G, Csepe V, Molnar M, Hegerl U, Karmos G. Intensitydependence of auditory evoked potentials in behaving cats.Electroencephalogr Clin Neurophysiol 1996; 100(6): 527-537.83. Juckel G, Hegerl U, Molnar M, Csepe V, Karmos G. Auditoryevoked potentials reflect serotonergic neuronal activity—astudy in behaving cats administered drugs acting on 5-HT1Aautoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology1999; 21(6): 710-716.84. Naatanen R, Picton T. The N1 wave of the human electricand magnetic response to sound: a review and an analysis ofthe component structure. Psychophysiology 1987; 24(4):375-425.85. Hegerl U, Gallinat J, Mrowinski D. Intensity dependence ofauditory evoked dipole source activity. Int J Psychophysiol1994; 17(1): 1-13.86. Brechmann A, Baumgart F, Scheich H. Sound-level-dependentrepresentation of frequency modulations in human auditorycortex: a low-noise fMRI study. J Neurophysiol 2002;87(1): 423-433.87. Mulert C, Jager L, Propp S, Karch S, Leicht G, Pogarell O, etal. Loudness dependence of the primary auditory cortex asan indicator of central serotonergic transmission: combinationof EEG and fMRI. Neuroimage 2004; 22: (suppl 1),TU356.88. Tuchtenhagen F, Daumann J, Norra C, Gobbele R, Becker S,Pelz S, et al. High intensity dependence of auditory evokeddipole source activity indicates decreased serotonergic activityin abstinent ecstasy (MDMA) users. Neuropsychopharmacology2000; 22(6): 608-617.89. Croft RJ, Klugman A, Baldeweg T, Gruzelier JH.Electrophysiological evidence of serotonergic impairment inlong-term MDMA (“ecstasy”) users. Am J Psychiatry 2001;158(10):1687-1692.90. Norra C, Mrazek M, Tuchtenhagen F, Gobbele R, Buchner H,Sass H, et al. Enhanced intensity dependence as a marker oflow serotonergic neurotransmission in borderline personalitydisorder. J Psychiatr Res 2003; 37(1): 23-33.91. Hegerl U, Juckel G. Intensity dependence of auditoryevoked potentials as an indicator of central serotonergicneurotransmission: a new hypothesis. Biol Psychiatry 1993;33(3): 173-187.92. Mulert C, Juckel G, Augustin H, Hegerl U. Comparisonbetween the analysis of the loudness dependency of theauditory N1/P2 component with LORETA and dipole sourceanalysis in the prediction of treatment response to the selectiveserotonin reuptake inhibitor citalopram in major depression.Clin Neurophysiol 2002; 113(10): 1566-1572.93. Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, StotzG, Kuss HJ, et al. The loudness dependency of the auditoryevoked N1/P2-component as a predictor of the acute SSRIresponse in depression. Psychopharmacology (Berl) 2000;148(4): 404-411.94. Pogarell O, Tatsch K, Juckel G, Hamann C, Mulert C, PopperlG, et al. Serotonin and dopamine transporter availabilitiescorrelate with the loudness dependence of auditory evokedpotentials in patients with obsessive-compulsive disorder.Neuropsychopharmacology 2004; 29(10):1910-1917.95. Gallinat J, Senkowski D, Wernicke C, Juckel G, Becker I,Sander T, et al. Allelic variants of the functional promoterpolymorphism of the human serotonin transporter gene isassociated with auditory cortical stimulus processing.Neuropsychopharmacology 2003; 28(3): 530-532.33
Page 3 and 4: CLINICAL EEG and NEUROSCIENCE ©200
Page 37: CLINICAL EEG and NEUROSCIENCE ©200

CLINICAL EEG and NEUROSCIENCE - Dynamic Memory Lab

Create successful ePaper yourself

Delete template?

Save as template?